0RAE Stock Overview
Amoéba S.A. develops biological biocides for the prevention of microbiological risk for water, crop protection and health sectors.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Amoéba S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.48 |
| 52 Week High | €0.69 |
| 52 Week Low | €0.38 |
| Beta | -0.021 |
| 1 Month Change | 22.19% |
| 3 Month Change | 0% |
| 1 Year Change | -16.14% |
| 3 Year Change | -77.89% |
| 5 Year Change | -78.66% |
| Change since IPO | -97.72% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RAE | GB Chemicals | GB Market | |
|---|---|---|---|
| 7D | 13.4% | 2.8% | 1.0% |
| 1Y | -16.1% | -35.0% | 3.0% |
Return vs Industry: 0RAE exceeded the UK Chemicals industry which returned -35% over the past year.
Return vs Market: 0RAE underperformed the UK Market which returned 3% over the past year.
Price Volatility
| 0RAE volatility | |
|---|---|
| 0RAE Average Weekly Movement | n/a |
| Chemicals Industry Average Movement | 7.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0RAE has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0RAE's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 22 | n/a | amoeba-nature.com |
Amoéba S.A. develops biological biocides for the prevention of microbiological risk for water, crop protection and health sectors. It develops applications using amoeba Willaertia magna C2c Maky. The company was incorporated in 2010 and is based in Chassieu, France.
Amoéba S.A. Fundamentals Summary
| 0RAE fundamental statistics | |
|---|---|
| Market cap | €22.83m |
| Earnings (TTM) | -€14.30m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.6x
P/E RatioIs 0RAE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RAE income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €1.71m |
| Gross Profit | -€1.71m |
| Other Expenses | €12.59m |
| Earnings | -€14.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 10.1% |
How did 0RAE perform over the long term?
See historical performance and comparison